| Nov 13 |
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
|
| Nov 10 |
Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.02 loss in 3Q 2023)
|
| Nov 8 |
Creative Medical Technology files to sell 0.83M shares of common stocks by selling shareholders
|
| Oct 24 |
Creative Medical to sell 418,552 shares at $4.42 in registered direct offering
|
| Oct 23 |
Creative Medical Technology to raise $1.9M via direct offering
|
| Oct 23 |
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
| Oct 4 |
Creative Medical Technology files for $50M mixed securities shelf
|
| Jul 24 |
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
|
| Jul 12 |
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
|
| Jun 24 |
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
|
